Vanda announces FDA approval of Fanapt® sNDA for maintenance treatment of schizophrenia
Vanda announced the FDA has approved Vanda's sNDA for Fanapt®, modifying and expanding the prescribing information to describe effectiveness of Fanapt® as a maintenance treatment for schizophrenia in adults. FDA approval was based on the results of the REPRIEVE placebo-controlled clinical study. May 27, 2016